Neuroblastoma: a pediatric cancer of the sympathetic nervous system

Characteristics and typical presentation

Neuroblastoma cells are poorly differentiated nerve cells that form solid masses. Common signs and symptoms depend on tumor location and spread. In the abdomen, a painless mass or distension is often noticed. Thoracic tumors may cause breathing or swallowing difficulties. When tumors compress spinal nerves, children can develop weakness or paralysis. Because many neuroblastomas produce catecholamines, biochemical signs may include elevated urinary or blood metabolites. Rare paraneoplastic phenomena — such as an involuntary eye movement disorder with myoclonus — can occur.

• Frequent clinical features: abdominal mass, pain, weight loss, bone pain from metastases.
• Possible biochemical clues: elevated catecholamine metabolites (e.g., VMA/HVA).
• Paraneoplastic syndromes: opsoclonus-myoclonus-ataxia and other immune-mediated effects.

Diagnosis and staging

Diagnosis combines imaging, laboratory testing, and tissue sampling. Imaging modalities include ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) to define tumor extent, and functional imaging such as meta-iodobenzylguanidine (MIBG) scans to detect catecholamine-avid disease. Biopsy or surgical resection provides tissue for microscopic examination; typical histology shows small round blue cells and may display Homer Wright rosettes. Laboratory evaluation often measures catecholamine metabolites. Staging systems and risk stratification take into account age at diagnosis, extent of spread, and tumor biology.

Current clinical assessment incorporates genetic and molecular features into prognosis. Tumor amplification of the MYCN oncogene, certain chromosomal deletions, and DNA ploidy are among the biological markers that influence risk categorization and treatment decisions.

Treatment approaches and prognosis

Management is tailored to the child’s age, disease stage, and tumor biology. Low-risk tumors — particularly small lesions in very young infants — can sometimes be observed because of spontaneous regression. Standard treatments include surgery to remove localized disease, chemotherapy for systemic control, radiation therapy for residual or refractory tumors, and stem cell transplantation for high-risk cases. In recent decades, immunotherapy (for example, anti-GD2 antibodies) and differentiation therapy using retinoids have improved outcomes for some high-risk patients.

• Local control: surgical resection when feasible.
• Systemic therapy: multi-agent chemotherapy and consolidation with autologous stem cell transplant for high-risk disease.
• Adjunct treatments: radiation, anti-GD2 immunotherapy, and differentiation agents.

Prognosis ranges from excellent for many infants with localized disease to guarded for older children with metastatic, biologically aggressive tumors. Late effects of therapy — including growth, endocrine, hearing, and fertility issues — are an important aspect of long-term care.

History, research directions, and notable facts

Neuroblastoma was recognized as a distinct pediatric tumor in the 20th century as neuropathology developed. Research continues to define the molecular drivers that determine tumor behavior and to translate those findings into targeted therapies. Notable features of neuroblastoma include its origin in embryonal neural crest cells and the rare phenomenon of spontaneous regression, especially in infants with specialized low-burden presentations sometimes called stage 4S. Genetic markers such as MYCN amplification are strongly associated with poor outcome and are central to risk-adapted treatment strategies.

Importance and resources

Because neuroblastoma affects very young children and can behave unpredictably, prompt evaluation by pediatric oncology teams is critical. Multidisciplinary care coordinates surgery, medical therapy, radiation, and supportive services. For further information on clinical guidelines, research updates, and family support, consult authoritative sources and professional organizations that specialize in pediatric oncology and rare childhood cancers. For basic information see sympathetic nervous system resources, for treatment guidelines see clinical guideline sources, and for support networks see patient and family resources. Additional scientific and educational materials are available from specialty pages on imaging (diagnostic imaging), pathology (pathology references), and survivorship care (long-term follow-up).